Peru - spaniolă - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

eurofarma peru s.a.c. - droguerÍa - irbesartan; hidroclorotiazida; - comprimido - por comprimido - - irbesartan y diuréticos

Peru - spaniolă - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

eurofarma peru s.a.c. - laboratorio - comprimido - por comprimido - - irbesartan y diuréticos

Peru - spaniolă - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

d.r.s. medical s.r.ltda. -

Peru - spaniolă - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

eurofarma peru s.a.c. - comprimido - por comprimido - irbesartan y diuréticos

Peru - spaniolă - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

eurofarma peru s.a.c. - laboratorio - comprimido - por comprimido - - irbesartan y diuréticos

Guatemala - spaniolă - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

eurofarma guatemala - comprimido

Guatemala - spaniolă - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

eurofarma guatemala - comprimido

Spania - spaniolă - Ecolab

ecolab deutschland gmbh -

Uniunea Europeană - spaniolă - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - rechazo del injerto - inmunosupresores - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Uniunea Europeană - spaniolă - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - leflunomida - arthritis, rheumatoid; arthritis, psoriatic - inmunosupresores - la leflunomida está indicado para el tratamiento de pacientes adultos con:artritis reumatoide activa como un 'antirreumáticos modificadores de la enfermedad de la droga' (dmard);activo de la artritis psoriásica. reciente o el tratamiento concurrente con hepatotóxicos o haematotoxic dmard (e. metotrexato) puede aumentar el riesgo de reacciones adversas graves; por lo tanto, el inicio del tratamiento con leflunomida debe considerarse cuidadosamente en relación con estos aspectos de beneficio / riesgo. por otra parte, el cambio de leflunomida a otro dmard sin seguir el procedimiento de lavado de también puede aumentar el riesgo de reacciones adversas graves, incluso mucho tiempo después de la conmutación.